

# Modeling Tumor Development

Yi Jiang

Theoretical Division

Los Alamos National Laboratory

*[jiang@lanl.gov](mailto:jiang@lanl.gov)*

*<http://math.lanl.gov/~yi>*



# Outline

- Cancer development overview
- What's been done?

*Overview of mathematical models for tumor growth*

- What have we done?

*A cell-based, multiscale model framework*

- What can our model do?

*Avascular tumor growth, angiogenesis, vascular growth*

- How good is our model?

*Pros and cons*

- Where are we going with such a model?

# Outline

- Cancer development overview
- What's been done?

*Overview of mathematical models for tumor growth*

- What have we done?

*A cell-based, multiscale model framework*

- What can our model do?


*Avascular tumor growth, angiogenesis, vascular growth*

- How good is our model?

*Pros and cons*

- Where are we going with such a model?


"I know that in the study of material things, **number, order and position** are the threefold clues to exact knowledge; that these three, in the mathematician's hands, furnish the 'first outlines for a sketch of the Universe'."



*On Growth and Form 1917*




# Colon Cancer Development




# The theory of Multi-Stage Carcinogenesis

- Many waves of Clonal Selection
- Clonal Selection occurs because of gene mutation
- Adaptation produces cells that proliferate more often than normal cells and undergo cell death (apoptosis) less often



Bielas and Loeb, 2005



## Models of cancer evolution


**'clonal selection model' (blue)**  
**'parallel evolution' model (red)**  
**an integrated model of cancer evolution (green)**

**histological snapshot of normal skin tissue (a), primary tumour (superficial  $b_1$  and deep  $b_2$ ), subcutaneous metastasis (c), metastasis in the lymph node (d) and metastasis in the lung (e)**

*Baudo et al. EMBO Reports 2009*



# Hallmarks of Cancer





- 6 essential phenotypes
- Many different mutation routes to cancer
- Cancer candidate genes
- Chemotherapies select and kill fast-growing cells
- Radiotherapies kill cells that reproduce more and repair less.

Hanahan & Weinberg, Cell 2000

# 3 Phases of Solid Tumor Growth



## Avascular tumor

- tumor spheroid  $10^6$  cells
- maximum diameter  $\sim 2\text{mm}$
- necrotic core
- thin proliferating rim





## Angiogenesis

- capillary network formation
- supplies tumor with blood




## Vascular growth, metastasis

- irregular structure
- highly invasive
- potentially fatal



# Avascular tumor growth (Multicellular Tumor Spheroid)

- *In vitro* 3D avascular tumor model.
- Precisely controlled external conditions with realistic tumor microenvironment; assays easy; data rich.
- Mimics growth dynamics of tumor *in vivo*.



Freyer, Sutherland

# Outline

- Cancer development overview
- **What's been done?**

*Overview of mathematical models for tumor growth*

- What have we done?

*A cell-based, multiscale model framework*

- What can our model do?

Avascular tumor growth, angiogenesis, vascular growth

- How good is our model?

*Pros and cons*

- Where are we going with such a model?



# Mathematical Models

- Empirical data fitting (map)

Gompertz

$$y(t) = a \exp[b \exp(-ct)]$$

$$b = \log(y(0)/a)$$




Marusic et al., *Cell Prolif* 1994



# Mathematical Models

- Compartmental model (PDEs)



$$\frac{\partial p}{\partial t} = \frac{\partial}{\partial x} \left[ \frac{p}{p+q} \frac{\partial(p+q)}{\partial x} \right] + g(c)p(1-p-q-n) - f(c)p$$

$$\frac{\partial q}{\partial t} = \frac{\partial}{\partial x} \left[ \frac{q}{p+q} \frac{\partial(p+q)}{\partial x} \right] + f(c)p - h(c)q$$

$$\frac{\partial n}{\partial t} = h(c)q$$

$$c = \frac{c_0 \gamma}{\gamma + p} [1 - \alpha(p+q+n)]$$

*Chaplain, Sherratt, Byrne, Anderson, Maini*

# Compartmental Models

- free boundary problems

$$\frac{\partial P}{\partial t} + \nabla \cdot (\vec{u}_P P) = (K_B(C) - K_Q(C))P + K_P(C)Q,$$

$$\frac{\partial Q}{\partial t} + \nabla \cdot (\vec{u}_Q Q) = K_Q(C)P - (K_D(C) + K_P(C))Q,$$

$$\nabla^2 C = \mu C,$$


$$\vec{u}_Q = \vec{u}_P + \chi \nabla C,$$

*Friedman, Cui, Hu, Byrne*

# Mathematical Models

- Biochemical kinetics

cancer cell receptor	$R, R_a, R_i$
fibroblast growth factor, FGF	$G$
urokinase plasminogen activator, uPA	$C$
tissue growth factor beta, $TGF\beta$	$I_a$
latent TGF beta, $TGF\beta_l$ ,	$I_i$
plasminogen	$P_g$
plasmin	$P_m$



$$\frac{\partial \eta}{\partial t} = \nabla \cdot \left\{ D_\eta \nabla \left[ \eta \ln \left( \frac{\eta}{\tau(g)} \right) \right] \right\} + \phi(g) \eta (1 - \eta/\eta_0) - \mu_\eta \eta,$$

$$\partial_t g = D_g \Delta g - \mu_g g + \frac{\sigma_g - \lambda_1 g}{1 + \nu_e \iota_a + g/K_m^1} \frac{\eta}{\eta_0},$$

$$\partial_t c = D_c \Delta c - \mu_c c + \frac{\lambda_1 g}{1 + \nu_e \iota_a + g/K_m^1} \frac{\eta}{\eta_0},$$

$$\partial_t p_m = D_p \Delta p_m - \mu_p p_m + \lambda_2^p c,$$


$$\partial_t \iota_a = D_a \Delta \iota_a - \mu_a \iota_a + \lambda_3 \iota_i p_m,$$

$$\partial_t \iota_i = D_i \Delta \iota_i - \mu_i \iota_i - \lambda_3 \iota_i p_m + \frac{\sigma_i}{1 + \nu_e \iota_a + g/K_m^1} \frac{\eta}{\eta_0}$$

Levine, Boushaba

# Hybrid Models


- Cellular automata coupled with PDE for O<sub>2</sub>, nutrients



Heiko Enderling

# Hybrid Models

- Cellular automata coupled with PDEs for O<sub>2</sub> dynamics, ECM dynamics, evolution...



Kasia Rajniak  
*Anderson, Guaranta*

# Multiscale Models

- John Lowengrub, Vittorio Cristini

*<http://math.uci.edu/~lowengrub/RESEARCH/tumor.php>*

- Philip Maini, Helen Byrne, Mark Chaplain

*<http://people.maths.ox.ac.uk/~maini/>*

*<http://www.maths.dundee.ac.uk/mbg/>*

- Yi Jiang

*<http://math.lanl.gov/~yi>*

# Outline

- Cancer development overview
- What's been done?

*Overview of mathematical models for tumor growth*

- **What have we done?**

*A cell-based, multiscale model framework*

- What can our model do?

Avascular tumor growth, angiogenesis, vascular growth

- How good is our model?

*Pros and cons*

- Where are we going with such a model?

# Modeling Tumor Development

- Cell dynamics: Cell growth and division, death, quiescence = cell cycle arrest, mutation
- Cell-cell interactions: adhesion, competition for space
- Cell-environment interactions


## Microenvironment:

- chemicals (absorption, production, and diffusion) = Nutrients, wastes, growth and inhibitory factors
- ECM/basement membrane – biomechanics
- Stromal cells




# Multicellular Multiscale Dynamics

- Complex emergent behavior and patterns
- Begin by using phenomenological descriptions of cell behaviors: biologically based rules, phenomenological terms for equations
- In many cases very complex pathways have fairly simple effects under conditions of interest, cell = blackbox
- Adding regulations back into the cells.



# ular Potts Model

$$\frac{\partial C_{O_2}}{\partial t} = D_{O_2} \nabla^2 C_{O_2} + a(x, y, z)$$




$$E = \sum_{\text{lattice sites}} J_{\tau(S_1)\tau(S_2)} [1 - \delta(S_1, S_2)] + \sum_{\text{cells}} \gamma \cdot (v - V^T)^2$$

$$p = \begin{cases} 1 & , \text{if } \Delta E < 0 \\ e^{-\Delta E/k_b T} & , \text{if } \Delta E \geq 0 \end{cases}$$

# Cellular Potts Model


- Cells are on a 3D lattice
- Each cell has a unique ID:  $S$
- Cells have types
- Cells interact at membrane
- Cell keeps a volume.



$$E = \sum_{lattice\ sites} J_{\tau(S_1)\tau(S_2)} [1 - \delta(S_1, S_2)] + \sum_{cells} \gamma \cdot (v - V^T)^2$$

$$p = \begin{cases} 1 & , \text{if } \Delta E < 0 \\ e^{-\Delta E/k_b T} & , \text{if } \Delta E \geq 0 \end{cases}$$

# Cell Sorting – differential adhesion



*Glazier et al. (1993,1995, 2001)*


$$E = \sum_{\text{lattice sites}} J_{\tau(S_1)\tau(S_2)} [1 - \delta(S_1, S_2)] + \sum_{\text{cells}} \gamma \cdot (v - V^T)^2$$

**Cell growth:**  $V^T \sim 2 V(t=0)$

**Cell division** —*when cell is ready to divide*—

- half of mother cell is assigned a new ID
- daughter cells inherit all properties of mother cell (*with a probability for mutation*).


# CELL CYCLE



# Protein Regulatory Network for Cell Cycle: G1→S

- **P15 = p15+p16+p18+p19**
- **P27=p27+p57**
- **Expression level: 0 or 1**
- **Local chemicals modify protein expression**

$$Factor\ level = \left( 1 + e^{-\alpha \cdot \left( \frac{gF - ihF}{initGF} - \theta \right)} \right)^{-1}$$



# Chemicals: Oxygen, Glucose, Lactate, growth factor, inhibitory factor

$$\frac{\partial C_{O_2}}{\partial t} = D_{O_2} \nabla^2 C_{O_2} + a(x, y, z) \quad (C_{O_2} = C_0^{O_2} \text{ at boundary})$$

$$\frac{\partial C_n}{\partial t} = D_n \nabla^2 C_n + b(x, y, z) \quad (C_n = C_0^n \text{ at boundary})$$

$$\frac{\partial C_w}{\partial t} = D_w \nabla^2 C_w + c(x, y, z) \quad (C_w = C_0^w \text{ at boundary})$$


$$\frac{\partial C_{gf}}{\partial t} = D_{gf} \nabla^2 C_{gf} + e(x, y, z) \quad (C_{gf} = C_0^{gf} \text{ at boundary})$$

$$\frac{\partial C_{if}}{\partial t} = D_{if} \nabla^2 C_{if} + f(x, y, z) \quad (C_{if} = C_0^{if} \text{ at boundary})$$



# Model details –

- Cells interact through surface adhesion as well as competition for space.
- Outcome of cell regulatory network together with growth (stress) determine quiescence.
- Necrosis condition: below threshold  $O_2$  or glucose or above threshold waste; necrotic cell maintains volume.
- Cells can shed from spheroid surface during mitosis.
- Cell clock. (Mutation)
- 1 cell cycle = 12 hours = 4 Monte Carlo Steps = 16 stages (G1 = 6 , S = 6, G2+M = 4)
- Maximum cell volume =  $4 \times 4 \times 4$  voxels =  $1200 \mu m^3$



# Outline

- Cancer development overview
- What's been done?

*Overview of mathematical models for tumor growth*

- What have we done?

*A cell-based, multiscale model framework*

- **What can our model do?**

*Avascular tumor growth, angiogenesis, vascular growth*

- How good is our model?




*Pros and cons*

- Where are we going with such a model?

**Day 2**


**Day 10**

**Day 18**




**0.08 mM  $\text{O}_2$  + 5.5 mM glucose**

Jiang et al. 2005



# Volume Growth

0.08 mM O<sub>2</sub> + 5.5 mM glucose



- **Necrosis condition for tumor cells:**


oxygen concentration below 0.02 mM,  
glucose concentration below 0.06 mM,  
waste (lactate) concentration above 8 mM.

**Tumor cells can survive in much harsher  
microenvironment than normal ones.**



- *Diffusion coefficient for growth factor and inhibitors*  
 $10^{-5} - 10^{-6} \text{ cm}^2/\text{hr}$

*Molecular weight ~ 70-100 KDa*


**0.08 mM O<sub>2</sub> + 5.5 mM glucose**



**0.28 mM O<sub>2</sub> + 16.5 mM glucose**






**0.08 mM O<sub>2</sub> + 10.5 mM glucose**



## tumor growth saturation

individual mechanisms



- Shedding
- Inhibitors
- Nutrient
- Mechanics





# P53 mediated tumor-cell growth competition

- P53 mutation leads to better survival in hypoxic conditions



*Kevin Flores*

# Outline

- Cancer development overview
- What's been done?

*Overview of mathematical models for tumor growth*

- What have we done?

*A cell-based, multiscale model framework*

- What can our model do?

*Avascular tumor growth, angiogenesis, vascular growth*

- How good is our model?

*Pros and cons*


- Where are we going with such a model?

Pros	Cons
Cell level phenotypes and interactions	Expensive computation
Cellular adhesion	Large scale growth – organ level development
Adding new modules, interactions	Energy based formulation not easy for force based mechanics

control


low dose

high dose




# Realistic tumor vessel network

Cells  
flowrate  
104  
93.9  
83.9  
73.9  
63.8  
53.8  
43.8  
33.8  
23.8  
13.8  
3.81




**Blood Flow-rate**

Cells  
O2  
leakiness  
2.41e+09  
2.3e+09  
2.16e+09  
2.02e+09  
1.88e+09  
1.73e+09  
1.59e+09  
1.45e+09



**Oxygen Permeability**



**Oxygen Distribution**

*Bryan Travis*

# Outline

- Cancer development overview
- What's been done?

*Overview of mathematical models for tumor growth*

- What have we done?

*A cell-based, multiscale model framework*

- What can our model do?


Avascular tumor growth, angiogenesis, vascular growth

- How good is our model?

*Pros and cons*

- Where are we going with such a model?

# To-do's



1


# Summary I (Tumor Growth)

- Cell-based approach
- Multiscale modeling
- Experimental data – starting point and validation
- Experimentally testable predictions and hypotheses
- Mechanistic understanding





# Tumor Induced Angiogenesis

- Secretion and diffusion of TAFs (VEGF)
- Endothelial cell activation: proliferation and migration
  - Signaling pathways
  - Chemotaxis
  - EC-ECM interactions
  - ECM remodeling
- Vasculature formation





<http://www.angio.org/>

## Continuous



Levine, et.al., *Bull. Math Biol.* (2001)




Wheeler, et.al., *Bull. Math. Biol.* (2005)

Discrete Treatment of Cells

Continuous + Binary Capillary Indicator Fcn





# Hypotheses/Assumptions



- o VEGF acts as chemo-attractant for EC.



- o Freely diffusing VEGF

- o **“Go or grow”**

- o Proliferation region:



1. right behind the tip


2. all activated cells except for tip cell

3. at the base of the sprout




- o ECs degrade ECM or secrete fibronectin

- o Sprout tip secretes MMPs that degrade ECM.



- Binding pro- & anti- angiogenic factors
- Regulating cell adhesion and migration





# Cellular model:

- Cell types: endothelial, normal, extracellular matrix, interstitial fluid

$$E = \sum_{\text{lattice sites}} J_{\tau(S_1)\tau(S_2)} [1 - \delta(S_1, S_2)] + \sum_{\text{cells}} \gamma \cdot (v - V^T)^2 + \sum_{EC} \mu C + \sum_{\text{cells}} \gamma' [1 - \delta(v, v')]$$


- Cell-matrix interaction: adhesion (**haptotaxis**), secretion and degradation, remodel and reorganizing
- Cell-VEGF interaction: binding, activation, sprout tip vs. proliferating vs. dormant; **chemotaxis**
- EC cell cycle = 18 hours = 5 MCS
- EC size = 16 x 16 = 100  $\mu\text{m}^2$

# VEGFA Dynamics



$$\frac{\partial V}{\partial t} = D \nabla^2 V - \lambda V - B(x, y)$$


$$B(x, y) = \begin{cases} \beta, & \text{if } \beta \leq V \text{ and } \{(x, y) \subset \text{EC}\}; \\ V, & \text{if } 0 \leq V < \beta \text{ and } \{(x, y) \subset \text{EC}\}; \\ 0, & \text{if } \{(x, y) \not\subset \text{EC}\}. \end{cases}$$




$\beta$  = maximal amount of VEGF bound by EC  
= total available receptor numbers








*Bauer, et al, Biophys J. (2007)*



## Proliferating region:




# VEGF Gradient Profiles







Iruela-Arispe, et. al. *J. Cell Biol.* (2005)







# Branching?






# Anastomosis









# cell recruitment from sprout base








# Matrix fiber alignment






# Effects of matrix density on sprout extension



*Bauer, Jackson,  
Jiang PLoS CB 2009*


# Interruption of Angiogenesis

$$\rho = 0.99$$





# High Anisotropy Induces Branching

$$\rho = 0.4$$




With matrix degradation



# Intracellular Signaling Network

*Bauer et al. 2009*



# Glass-type model

- State transition dynamics  
→ Signal transduction

*Glass, JTB, 1973.*  
*Glass, JCP, 1975.*

$$x_i(t) \in [0, 1], \quad X_i(t) = H(x_i - \theta)$$

$$X_i(t) = \begin{cases} 1, & x_i(t) \geq 1/2 \\ 0, & x_i(t) < 1/2 \end{cases}$$

- Variables in biological systems are usually continuous
- There are few mechanisms for synchronous updating of the state

## Discrete Boolean

$$X_i(t+1) = f_i(X(t))$$

$$f_H = \frac{\lambda x^n}{\theta^n + x^n}$$

## Continuous Boolean

$$\frac{dx_i(t)}{dt} = f_i(X_{ri}^1(t), \dots, X_{ri}^{ki}(t)) - x_i(t)$$

## Continuous Stochastic Boolean

$$\frac{dx_i(t)}{dt} = \left| f_i(X_{ri}^1(t), \dots, X_{ri}^{ki}(t)) - \delta(t) \right| - x_i(t)$$

$$\delta(t) = \begin{cases} 1, & \text{with probability } p \\ 0, & \text{with probability } 1 - p \end{cases}$$


# Glass-type model

- Boolean dynamics  $f_i(X_{ri}^1(t), \dots, X_{ri}^{ki}(t))$

**ECM-Integrin = ITG**  
**VEGF- VEGFR2 = RTK**  
**VE-cadherin = cadherin**


**p53 = !ITG**  
**PIP3 = PI3K && ! PTEN**  
**Rac1 = PIP3 && ! RhoA**  
**MEK1 = Raf-1 || Rac1**  
**...**

**Motility = Actin**  
**Proliferation = cyclin D1**  
**Apoptosis = Bad && !b-catein**








# cell phenotypes




# Robust to internal noise




# Fast response to signals




# Feedback scheme 2 unstable



# Apoptotic switch sensitive



# Multi-Scale Model of Tumor Angiogenesis



## Cellular model

- Cell types: endothelial, normal, extracellular matrix, interstitial fluid

$$E = \sum_{\text{lattice sites}} J_{\tau(S_1)\tau(S_2)} [1 - \delta(S_1, S_2)] + \sum_{\text{cells}} \gamma \cdot (v - V^T)^2 + \sum_{EC} \mu C + \sum_{\text{cells}} \gamma' [1 - \delta(v, v')]$$


haptotaxis, chemotaxis

## ExtraCellular chemical

$$\frac{\partial V}{\partial t} = D \nabla^2 V - \lambda V - B(x, y)$$



## Static ECM

# Phenotype Distribution









# Extension Speed and Branching Mediated by Matrix Density



# Branching & Anastomosis




# Emergent Phenomenon: Brush Border Effect



Bauer Thesis 07

# Apoptosis:


## Receptor dialing as Pro- and Anti-angiogenic therapy



$\uparrow T_I \rightarrow \uparrow \text{Apoptosis}$

$\uparrow T_R \rightarrow \uparrow \text{Apoptosis}$



Avasin  
PTK787/ZK222584






# Experimental validation

Luisa Arispe lab




# Cell-ECM Interactions



*David Weitz lab*




# ECM Mechanics



*Weitz lab*


# Integrins

- 17 Integrin- $\alpha$  chains + 8 Integrin- $\beta$  chains  
→ 25 Integrins
- each integrin selectively binds ECM proteins  
ITG- $\alpha 1/\beta 1$ : collagen-I, collagen-IV and laminin; ITG- $\alpha 5\beta 1$ : fibronectin
- each integrin is expressed differently in different cell types




IMGT.org

# FAK Pathway



*ProteinLounge.com*


# Mechano-transduction



Weitz lab

Growth, proliferation, polarization, migration,  
regulation of MMPs, cadherins...

# Dimensionality



*Doyle et al. JCB Report, 2009*



# Cell-Migration Hike at q-Bio 09

when: Friday afternoon (8/7/09)


where: Santa Fe ski basin day hike trail, meet at St. John's College

who: anyone interested



# Tumor Invasion

- Migration: brain tumor (glioma, glioblastoma), breast cancer...
- <http://www.youtube.com/marcuslab>



Deryugina & Quigley, 2008

# Summary

- Cell – tissue – organ level mechanistic study
- Cell-based, multiscale modeling framework for tumor growth and angiogenesis.
- Test hypotheses and generate hypotheses that can be tested experimentally
- Mathematical Model vs. in vitro model vs. in vivo animal model vs. in vivo human (model) vs. clinical cases
- ‘Simple but not simpler’



Jim Freyer, Bryan Travis  
Jelena Pjesivac, Charles Cantrell,  
Amy Bauer, Kejing He,  
Kevin Flores, Zhiying Sun



Trace Jackson, **Jacques Nor**  
Amy Bauer

**UCLA**

Tom Chen, Luisa Iruela-Arispe



Evan Zamir